Flu vaccine may protect against adverse events after SARS-CoV-2
Aug 17, 2021
Individuals who had received a flu vaccination had lower risks for sepsis, stroke and deep vein thromboses as well as emergency department and ICU admissions
Neutralization titers against omicron up with mRNA-1273 boost
Jan 28, 2022
After a mRNA-1273 (Moderna) boost, neutralization titers against the omicron variant were 20 times higher than than those at one month after second dose.
Rates of COVID-19, severe illness lower with BNT162b2 booster dose
Dec 09, 2021
A second study shows a reduction in the rate of death due to COVID-19 with a booster dose of BNT162b2 (Pfizer–BioNTech).
Thrombosis, thrombocytopenia syndrome up after Ad26.COV2.S
Jan 28, 2022
Rates of 3.83 per million vaccine doses for Ad26.COV2.S (Johnson & Johnson) have been reported, versus 0.00855 per million for mRNA-based vaccines such as Pfizer-BioNTech and Moderna.
Single dose of RSV vaccine prevents acute respiratory infection in seniors
Feb 17, 2023
High vaccine efficacy was seen against RSV A and B subtypes, across age groups among those aged 60 years and older, and for those with coexisting conditions.
Risk for blood clots after COVID-19 vaccination explored
Mar 11, 2022
Two studies show an increase in intracranial venous thrombosis, thrombocytopenia for those younger than 70 years and in CVST after ChAdOx1-S.
Focus on briefs: Resident security
By
John Hall
Dec 03, 2023
Costs, along with changing attitudes, help fuel growth in deprescribing, Older Americans have access to more vaccines than ever, but increasing numbers cause concern for some individuals
Vaccination ups infection-acquired immunity against SARS-CoV-2
Mar 01, 2022
Two doses of the BNT162b2 (Pfizer-BioNTech) vaccine were linked to high short-term protection against infection, which wanes after six months.
RSVpreF safe, effective for preventing respiratory syncytial virus illness in seniors
Apr 10, 2023
The findings seen in phase 3 trial of adults aged 60 years and older receiving a single intramuscular injection of RSVpreF vaccine.
FDA panel to weigh improved booster shots from Moderna, Pfizer
Jun 27, 2022
Both Pfizer and Moderna have been testing updated booster shots that target the omicron variant.